[go: up one dir, main page]

BR9808030A - Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos - Google Patents

Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos

Info

Publication number
BR9808030A
BR9808030A BR9808030-0A BR9808030A BR9808030A BR 9808030 A BR9808030 A BR 9808030A BR 9808030 A BR9808030 A BR 9808030A BR 9808030 A BR9808030 A BR 9808030A
Authority
BR
Brazil
Prior art keywords
thio
cyclic derivatives
certain cyclic
acid amide
acylamino acid
Prior art date
Application number
BR9808030-0A
Other languages
English (en)
Inventor
Cynthia Anne Fink
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9808030A publication Critical patent/BR9808030A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/32Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente de Invenção:<B>"CERTOS DERIVADOS CìCLICOS DE AMIDA DE ACILAMINOáCIDO TIO-SUBSTITUìDOS"<D>. Descobriu-se o composto da fórmula I onde R, R~ 1~, R~ 2~, R~ 3~, R~ 4~, A e n são conforme definidos; sais farmaceuticamente aceitáveis dos mesmos; bissulfetos correspondentes aos referidos compostos da fórmula I onde R~ 4~ é hidrogênio; métodos para a preparação dos mesmos; composições farmacêuticas compreendendo os referidos produtos; e um método de inibição da atividade do TNF-alfa e da mataloproteinase destruidora de matriz e de tratamento das doenças ou condições dependentes do TNF-alfa e da metaloproteinase de matriz, por exemplo, condições inflamatórias, osteoartrite, artrite reumatóide e tumores, em mamíferos usando estes compostos.
BR9808030-0A 1997-03-20 1998-03-18 Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos BR9808030A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3984597P 1997-03-20 1997-03-20
PCT/EP1998/001584 WO1998042662A1 (en) 1997-03-20 1998-03-18 Certain cyclic thio substituted acylaminoacid amide derivatives

Publications (1)

Publication Number Publication Date
BR9808030A true BR9808030A (pt) 2000-03-08

Family

ID=21907632

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808030-0A BR9808030A (pt) 1997-03-20 1998-03-18 Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos

Country Status (24)

Country Link
US (2) US6034136A (pt)
EP (1) EP0966439B1 (pt)
JP (1) JP4275743B2 (pt)
KR (1) KR20000076428A (pt)
CN (1) CN1264817C (pt)
AT (1) ATE242209T1 (pt)
AU (1) AU734967B2 (pt)
BR (1) BR9808030A (pt)
CA (1) CA2283643C (pt)
CZ (1) CZ293706B6 (pt)
DE (1) DE69815307T2 (pt)
DK (1) DK0966439T3 (pt)
ES (1) ES2201480T3 (pt)
HU (1) HU226645B1 (pt)
ID (1) ID23808A (pt)
IL (1) IL131752A (pt)
NO (1) NO314079B1 (pt)
NZ (1) NZ337558A (pt)
PL (1) PL195389B1 (pt)
PT (1) PT966439E (pt)
RU (1) RU2193556C2 (pt)
SK (1) SK284127B6 (pt)
TR (1) TR199902303T2 (pt)
WO (1) WO1998042662A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック アール アンド ディ リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
AU2003294917A1 (en) * 2002-12-20 2004-07-14 Novartis Ag Device and method for delivering mmp inhibitors
GB0310724D0 (en) * 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
WO2007141029A1 (en) * 2006-06-08 2007-12-13 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Specific protease inhibitors and their use in cancer therapy
WO2009070497A1 (en) * 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
WO2019210160A1 (en) * 2018-04-26 2019-10-31 Brandeis University Antibacterial compounds, compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
SU1361143A1 (ru) * 1985-07-12 1987-12-23 Пермский фармацевтический институт Способ получени фенилкарбамоилметиловых эфиров ароилтиоуксусных кислот
GB8729804D0 (en) * 1987-12-22 1988-02-03 Beecham Group Plc Novel compounds
WO1991009840A1 (en) * 1989-12-22 1991-07-11 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
JPH0592948A (ja) * 1991-02-06 1993-04-16 Yoshitomi Pharmaceut Ind Ltd プロピオン酸アミド誘導体およびその医薬用途
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
CN1193978A (zh) * 1994-10-05 1998-09-23 奇罗斯恩有限公司 肽基化合物和它们作为金属蛋白酶抑制剂的医疗用途
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use

Also Published As

Publication number Publication date
EP0966439A1 (en) 1999-12-29
AU7037298A (en) 1998-10-20
DE69815307T2 (de) 2004-04-29
WO1998042662A1 (en) 1998-10-01
HUP0002122A2 (hu) 2001-05-28
IL131752A0 (en) 2001-03-19
HUP0002122A3 (en) 2001-12-28
RU2193556C2 (ru) 2002-11-27
EP0966439B1 (en) 2003-06-04
CN1264817C (zh) 2006-07-19
IL131752A (en) 2004-09-27
CA2283643C (en) 2008-09-23
US6034136A (en) 2000-03-07
AU734967B2 (en) 2001-06-28
ATE242209T1 (de) 2003-06-15
US6201133B1 (en) 2001-03-13
CA2283643A1 (en) 1998-10-01
NZ337558A (en) 2001-06-29
NO994482L (no) 1999-09-16
CZ332599A3 (cs) 1999-12-15
CZ293706B6 (cs) 2004-07-14
ID23808A (id) 2000-05-11
HU226645B1 (en) 2009-05-28
PT966439E (pt) 2003-10-31
CN1251092A (zh) 2000-04-19
NO314079B1 (no) 2003-01-27
NO994482D0 (no) 1999-09-16
SK127599A3 (en) 2000-03-13
DE69815307D1 (en) 2003-07-10
TR199902303T2 (xx) 1999-12-21
JP2001524959A (ja) 2001-12-04
KR20000076428A (ko) 2000-12-26
ES2201480T3 (es) 2004-03-16
PL335607A1 (en) 2000-05-08
PL195389B1 (pl) 2007-09-28
JP4275743B2 (ja) 2009-06-10
SK284127B6 (sk) 2004-09-08
DK0966439T3 (da) 2003-09-22

Similar Documents

Publication Publication Date Title
BR9808030A (pt) Certos derivados cìclicos de amida de acilaminoácido tio-substituìdos
BR0313460A (pt) Derivados de naftaleno como inibidores de metaloproteinase da matriz
BR9815169A (pt) &#34;método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença.&#34;
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BRPI0409227B8 (pt) &#34;composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)&#34;
BR0313724A (pt) Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
BR9916851A (pt) Ligantes receptores de tireóide e método ii
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BG108806A (en) IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
GEP20043265B (en) Acetylenic alpha -Amino Acid-Based Sulfonamide Hydroxamic Acid TACE Inhibitors, Methods for Their Production, Pharmaceutical Compositions Containing the Same and Their Use for Inhibiting Pathological Conditions Mediated by TNF- Alpha Ferment (TACE) With Mammalians
BR9900856A (pt) Antibioticos macrolideos de 3,6-cetal e enol-éter
ECSP055595A (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
BR9810911A (pt) Composto, e, processo para tratar câncer em um mamìfero
EA200100809A1 (ru) 2,3,4,5-тетрагидро-1h-[1,4]бензодиазепин-3-гидроксамовые кислоты как ингибиторы матриксных металлопротеиназ
BR0316629A (pt) Uréias e carbamatos substituìdos
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
BR0313459A (pt) Derivados monocìclicos como inibidores de metaloproteinases de matriz
DE69013511T4 (de) Aminosäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
BR112022019510A2 (pt) Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher
BR0313384A (pt) Derivados de cromona como inibidores de metaloproteinases de matriz
BRPI0406823A (pt) Inibidores amida e éster de metaloproteinases de matriz

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07C 323/53, C07C 323/60, C07C 327/32, C07D 213/56, C07D 213/75, C07D 213/81, C07D 213/82, C07D 333/24, C07D 333/38, A61K 31/16, A61K 31/265, A61K 31/5375, A61K 31/21, A61P 19/02, A61P 29/00, 61P 35/00

Ipc: C07C 323/53 (2007.01), C07C 323/60 (2007.01), C07C

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 13A E 14A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 13A E 14A ANUIDADES.